Home Neoplasma 2020 Neoplasma Vol.67, No.6, p.1384–1390, 2020

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.6, p.1384–1390, 2020

Title: Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib
Author: Y. CHENG, F. C. DU, F. Q. FANG, Z. J. DUAN, W. LEI, K. G. SHI

Abstract: The clinical efficiency and adverse reactions of anlotinib in metastatic colorectal cancer (mCRC) as a third-line treatment compared with chemotherapy and regorafenib or fruquintinib was explored in this study. Clinical data from 105 mCRC patients who failed at least two lines of chemotherapy were collected.
The patients were divided into three groups based on their third-line therapeutic regimen: third-line chemotherapy only (group A); anlotinib (group B); and fruquintinib or regorafenib (group C). The result showed that the ORR and DCR of group B (14.29%, 85.71%) were higher than those of group A (0%, 40.00%). The ORRs of group B and group C were 14.29% and 20.00%, respectively. Group B and group C had the same DCR, 85.71%. The mean PFS values of group B (3.46 months) and group C (3.33 months) were longer than that of group A (2.25 months) (χ2 = 84.255, P intestinal reaction were more common in group A than in group B and group C (P apy and similar to regorafenib or fruquintinib. The associated adverse reactions are tolerable.

Keywords: metastatic colorectal cancer; anlotinib; chemotherapy; fruquintinib; regorafenib
Published online: 13-Jul-2020
Year: 2020, Volume: 67, Issue: 6 Page From: 1384, Page To: 1390

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.